New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

February 2014

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014

Press Releases / By

CRANBURY, N.J., Feb. 18, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2013.  Recent HighlightsPivotal Phase 3 clinical trials of bremelanotide for Female Sexual …

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014 Read More »

Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results

Press Releases / By

CRANBURY, N.J., Feb. 13, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February …

Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results Read More »

Scroll to Top